An article in BioWorld Today, Jan. 9, 1998, on Genentech Inc.'s thrombopoietin should have mentioned that Genetics Institute Inc., of Cambridge, Mass., received FDA approval in November 1997 of Neumega, recombinant interleukin-11, for treatment of thrombocytopenia associated with cancer chemotherapy.